Investing inWhat Matters Most2024
Forging Companies
at theCutting Edge of
Breakthroughs
2024 was an important year for MPM BioImpact and our portfolio companies.
We welcomed several new colleagues and established our global footprint, including opening an office in Asia. Our portfolio companies celebrated the FDA approval of three new medicines, and advanced the next generation of novel product candidates through clinical and preclinical development.As we welcome 2025, we look forward to harnessing our 30+ years’ experience in venture capital and our decade-long commitment to public investing to continue transforming scientific breakthroughs and innovative technologies into life-saving medicines.”
Pioneering Leadership
Promotion
Recent Additions
Frank Neumann, M.D., Ph.D.
Entrepreneur Partner
Accomplished clinical development executive and cell therapy/oncology expert
“I’m thrilled to join MPM BioImpact and contribute to its patient-focused mission. The firm’s scientific rigor and expertise in creating companies from the ground up has catalyzed the development of many novel, life-saving therapies for patients in need.”
Michael Ehlers, M.D., Ph.D.
Entrepreneur Partner
Esteemed biotechnology executive and research and development leader
“MPM BioImpact stands alone in its commitment to meaningfully support companies at every stage of development. I am thrilled to join the team and look forward to supporting portfolio companies as a true strategic partner.”
Brian Shuster, M.B.A.
Entrepreneur Partner
Accomplished healthcare corporate development executive
Carolyn Bertozzi, Ph.D.
Future Chairperson of MPM BioImpact Scientific Advisory Board
2022 Nobel Laureate, Stanford University; Co-Founder of 2 MPM BioImpact companies
Visionary Companies Advancing thethe Future of Medicine**
Creating fully engineered circular RNA (oRNA) therapeutics – an entirely new class of RNA medicines.
Orna Therapeutics Establishes an Up To $4 Billion Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Our collaboration with Vertex, an expert in developing novel approaches for treating hemoglobinopathies, further validates Orna’s extra-hepatic LNP delivery platform and leadership in next generation RNA medicines. The efforts advanced under this collaboration, together with Orna’s lead panCAR™ pipeline programs in autoimmune and oncology, have the potential to deliver immense patient impact.”
Entrepreneur Partner, MPM BioImpact
Entrepreneur Partner, MPM BioImpact
Entrepreneur Partner, MPM BioImpact
In May, Orna Therapeutics Acquired ReNAgade Therapeutics
Realizing the curative power of alpha radiopharmaceuticals for mainstream cancer care.
Aktis Oncology Enters into Strategic Collaboration with Lilly to Discover and Develop Novel Anticancer Radiopharmaceuticals
Our strategic collaboration with Lilly leverages Aktis’ unique miniprotein radiopharmaceutical platform capabilities to address novel targets, while delivering a safe and effective clinical profile. We are pleased to partner with Lilly on efforts to increase the number of patients that can derive meaningful clinical benefit from targeted radiopharmaceuticals.”
Entrepreneur Partner, MPM BioImpact
Our Companies Aim to Create Clinically Meaningful Drugs that will Transform Patient Lives
Added 3 FDA approved drugs in 2024
FDA APPROVED DRUGS inMPM BioImpact-Led Companies*
Portfolio Company Clinical Accomplishments**
Semma Therapeutics
Vertex to Advance VX-880 into a Pivotal Phase 1/2/3 Study
Semma acquired by VRTX in 2019
Reunion Neuroscience
First Patient Dosed in Phase 2 Clinical Trial for the Treatment of Postpartum Depression
Dyne Therapeutics (DYNE)
Positive Clinical Data from Phase 1/2 Trial in Duchenne Muscular Dystrophy
Insmed (INSM)
Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
Crinetics Pharmaceuticals (CRNX)
FDA Acceptance for New Drug Application for Paltusotine for Adult Patients with Acromegaly
Edgewise Therapeutics (EWTX)
Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy
5 Acquisitions**Public Portfolio Totaling~$25B*
*Based on date of closing
“The $25B of M&A activity across our public portfolio this year reflects MPM BioImpact’s deep research, clinical development and regulatory expertise, which we leverage to identify and invest in companies at the forefront of innovation, each with the potential to create tremendous value. As pharma continues to lean on biotech for access to new assets and technologies, our focus remains in helping transform scientific breakthroughs into life-saving medicines.”
Christiana Bardon, M.D., M.B.A.Managing PartnerMPM BioImpact
“With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise. Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realize the full impact and value of their investigational medicines for patients with unmet needs.”
– Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis
MPM BioImpact in Action
MPM BioImpact is a
World-leading Biotech Impact Investor
MPM BioImpact generates profound human and social impact, enabling innovative science to become transformative medicines and expanding access to healthcare for people worldwide, while delivering sustainable financial returns to its clients.
